New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2013
19:37 EDTACT, NVS, MYL, VRXNovartis weighing Actavis bid, WSJ reports
Valeant Pharmaceuticals (VRX) and Mylan (MYL) are weighing options after approaches made to Actavis (ACT) were rebuffed, and a report by the Wall Street Journal, citing a source, says Novartis (NVS) is weighing whether to launch its own bid for Actavis. Reference Link
News For NVS;MYL;VRX;ACT From The Last 14 Days
Check below for free stories on NVS;MYL;VRX;ACT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 21, 2014
07:55 EDTACTActavis volatility expected to move on Pfizer considering new target report
Actavis (ACT) volatility is expected to move on Pfizer (PFE) considering other overseas alternatives, Bloomberg reports. Overall option implied volatility of 27 is near its 26-week average of 31 according to Track Data, suggesting decreasing price movement.
07:47 EDTACTPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
07:38 EDTACTSupernus announces paragraph IV Abbreviated NDA filing for Trokendi XR
Subscribe for More Information
August 20, 2014
17:59 EDTVRXAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTVRXAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
11:44 EDTMYLMylan completes second bidding round for GSK prescription portfolio, WSJ says
Mylan (MYL), TPG Capital, Advent International, KKR (KKR), Warburg Pincus and a few Indian prescription manufacturers have completed the second round of bidding for GlaxoSmith Kline's (GSK) portfolio of mature medications, according to The Wall Street Journal, citing people familiar with the sales process. GSK noted that it aims to sell a portfolio of drug brands in the U.S. and EU with yearly sales of approximately $1.66B. Reference Link
11:33 EDTMYLMylan into second round of bidding for GSK drug portfolio, WSJ reports
Subscribe for More Information
10:53 EDTVRXAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTVRXAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:07 EDTVRXSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
17:14 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTVRXAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
13:13 EDTVRXAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
11:44 EDTMYLMylan launches generic Precedex Injection
Subscribe for More Information
11:18 EDTACTDepomed announces favorable ruling in Gralise case
Subscribe for More Information
10:32 EDTACTDepomed higher after favorable ruling in Gralise case
Subscribe for More Information
07:26 EDTACTActavis confirms positive results from RECLAIM pivotal Phase III studies
Subscribe for More Information
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use